🌟 Just 5 days to go until we see you at EUROTOX Congress 2024 in Copenhagen, Denmark! 🌟 We are excited to attend and exhibit at EUROTOX 2024, kicking off this Sunday, September 8. 👋 Stop by Booth 📍#51 to explore our latest innovations in liver toxicology research. Whether you’re focused on hazard identification, translational studies, or clinical toxicology, our extensive portfolio has everything you need to take your research to the next level. Don’t miss the chance to check out our posters and gain insights from our scientists: 🔹Species-specific liver microtissues: a set of micro-physiological systems to study translational hepatotoxicity in safety assessment 🗣️ Dr. Maria Vittoria Colombo, Scientist / Product Coordinator 🗓️ Monday, 9 September 2024, 15:30 - 16:00 & Tuesday, 10 September 2024, 9:30 - 10:00 📍 Carstensen, Cinema room CABINN Hotel, EUROTOX 2024 📜 P12-05 🔹Early Detection of Hepatotoxic Compounds in Drug Development: Leveraging the Potential of Human Liver Microtissues for Predictive Screening 🗣️ Dr. Anna Borgström, Deputy VP Liver Safety 🗓️ Monday, 9 September 2024, 15:30 - 16:00 & Tuesday, 10 September 2024, 9:30 - 10:00 📍 Carstensen, Cinema room CABINN Hotel, EUROTOX 2024 📜 P12-07 Let’s join forces, share insights, and shape the future of liver safety together at EUROTOX 2024! For more details on our activities and updates, visit our website. You’ll find the link in the comments below 👇 See you soon! 🌟 Jan Lichtenberg, Paul Edgard Clémençon, Madhu Lal Nag, MBS PhD, Bruno Filippi, Bärbel Ulmer, Christine Schwenk, Wolfgang Moritz, Arumugham (Ragoo) Raghunathan, Arnab China, PhD, Sue Grepper, PhD, Lola Fäs, Monika Tu, Katarzyna Sanchez, Hajnalka Varga, Karolina Kaczmarska, Rositsa Hadzhipetrova, Tina Žel #EUROTOX2024 #LiverToxicology #ResearchInnovation #Collaboration #TheModelofExcellence™ #InSphero
InSphero
Biotechnologieforschung
Schlieren, Schweiz 11.924 Follower:innen
Reliable, reproducible, and scalable 3D in vitro platforms for drug safety & efficacy testing | The Model of Excellence™
Info
InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug safety and efficacy testing in a way that empowers researchers to reach their full potential. Our innovative spheroid-based models allow for more effective and safe therapies to get to the clinic faster due to our superior robustness, reliability, reproducibility, and scalability. InSphero’s goal is to help researchers fuel a new era of drug discovery through comprehensive products and services for: - Liver safety - Liver disease - Islet Biology - Oncology & Immunology
- Website
-
http://www.insphero.com
Externer Link zu InSphero
- Branche
- Biotechnologieforschung
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Schlieren, Schweiz
- Kunst
- Privatunternehmen
- Gegründet
- 2009
- Spezialgebiete
- 3D cell culture, Cell-based assays, Drug screening, Toxicology, Drug discovery, Liver Disease, Islet Biology, Oncology & Immunology, Spheroid Microplates, Organ-on-a-Chip Technologies und 3D in vitro technology
Orte
-
Primär
Wagistrasse 27A
Schlieren, Schweiz 8952, CH
-
74 Orion Street
Brunswick, ME 04011, US
Beschäftigte von InSphero
-
Jan Lichtenberg
Transforming 3D drug discovery and safety, CEO of InSphero, Board Member
-
Frauke Greve
-
Madhu Lal Nag, MBS PhD
Chief Scientific Officer
-
Thomas Pfisterer
Director Direct Investments (CIO-DI) @ Single Family Investment Office with strong management, strategy, finance, M&A and corporate development skills
Aktualisierungen
-
InSphero hat dies direkt geteilt
It was a pleasure to have Jan Lichtenberg, CEO and co-founder of InSphero as a speaker for our 17th BC Seminar Series. Jan Lichtenberg gave us an insight into ‘The Power of 3D Microtissue Models in Advancing Patient-Centric Research’. Thank you very much for this exciting lecture!
-
#TGIF! We hope your weather is as good as it is here in Zürich At InSphero some afternoons look just like this #IYKYK 😉 🍢🍧🍿🥂 Beers & Spheres is a monthly event where we get together and enjoy good food, drinks, music, and most importantly - each other's company! 🙌 What a better way to wish you a nice weekend from our team! Enjoy the last bits of summer ☀️ Jan Lichtenberg Wolfgang Moritz Madhu Lal Nag, MBS PhD Paul Edgard Clémençon Filip Henzler Bruno Filippi Burcak Yesildag Francisco Verdeguer Laure-Anne Ligeon Olivier Frey Marion Bavand Stina Näslund David Fluri Dr. Henriette Schneider Rositsa Hadzhipetrova #teambuilding #teamspirit #afterworkdrinks
-
📸 A few snapshots from yesterday's presentation at the #NEXUS Personalized Health Technologies conference, organized by ETH Zürich 📸 🤩 We were happy to join the 4th edition of the event and explore the present and future directions in personalized health technologies. 📢 Our Senior Research Associate in Liver Disease, Philip Vonschallen, gave an oral presentation titled: “Screening and comparison of current clinical candidates in #MASH using human #liver #spheroids” 🔍 Would you like to learn more about how we are overcoming the challenges in #MASH #Screening? Check out the link in comments 👇 Francisco Verdeguer Radina Kostadinova, PhD Jesus Francisco Glaus Garzon Joel Zvick Angelina Freitag Paul Edgard Clémençon Arumugham (Ragoo) Raghunathan Bärbel Ulmer Christine Schwenk Arnab China, PhD Sue Grepper, PhD Madhu Lal Nag, MBS PhD Tina Žel Rositsa Hadzhipetrova #MASH #invitromodels #NAMs #3dliver #liverdisease #liverdiscovery
-
✈️ Off to Copenhagen, Denmark, this September! ✈️ Are you getting ready for the EUROTOX Congress 2024 from 🗓️ September 8th to 11th—we certainly are! 👋 Visit us at Booth 📍 #51, where we'll be showcasing our cutting-edge innovations in liver toxicology research. Whether you're focused on hazard identification, translational studies, or clinical toxicology, our comprehensive portfolio has what you need to elevate your research. We’re excited to connect with fellow researchers, scientists, and industry professionals to explore the latest trends and breakthroughs in toxicology. Let’s collaborate, exchange ideas, and shape the future of Liver Safety together at EUROTOX Congress 2024! For more details on our activities and updates, visit our website. You’ll find the link in the comments below 👇 See you there! 🌟 Jan Lichtenberg Paul Edgard Clémençon Madhu Lal Nag, MBS PhD Bruno Filippi Anna Borgström Maria Vittoria Colombo Bärbel Ulmer Christine Schwenk Wolfgang Moritz Arumugham (Ragoo) Raghunathan Arnab China, PhD Sue Grepper, PhD Lola Fäs Monika Tu Katarzyna Sanchez Hajnalka Varga Karolina Kaczmarska Rositsa Hadzhipetrova Tina Žel #EUROTOX2024 #LiverToxicology #ResearchInnovation #Collaboration #TheModelofExcellence™ #InSphero
-
⏪Throwback Thursday... 🎥 Akura™ #Organonchip: The Beginning with Dr. Olivier Frey, Vice President of Technologies & Platforms 7 years ago we embarked on the journey of reimagining what industry-ready Organ-on-Chip technology should look like – fast-forward to 🗓 2024 we have come a long way! We are proud to enable researchers to address complex biological questions with our Akura™ #OoC platforms: ✔️ Based on our reliable and reproducible 3D InSight™ #Microtissues ✔️ Encompass gravity-driven flow without pumps and heavy operational systems ✔️ Are ready to be incorporated into the routine processes of the #pharmaceutical and #biotechnology industry thanks to their high #scalability Discover Akura™ Organ-on-Chip Platforms via the link in comments 👇 Jan Lichtenberg Madhu Lal Nag, MBS PhD Paul Edgard Clémençon Lisa Hoelting Frauke Greve Judi Wardwell-Swanson Ozlem Yavas Grining Agnieszka Pawlowska Tamara Häfeli Arumugham (Ragoo) Raghunathan Arnab China, PhD Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Tina Žel Rositsa Hadzhipetrova #TheModelofExcellence #3dinvitro #NAMs #drugdiscovery
-
InSphero hat dies direkt geteilt
Good company in a journey makes the way seem shorter, as Izaak Walton wrote. And at InSphero , I feel in truly great company with excellent scientists and managers. Today, I want to take a moment to express my heartfelt appreciation for our Chief Financial Officer, Filip Henzler, who joined InSphero 18 months ago. Since day one, Filip has been nothing short of extraordinary in transforming our business processes, enhancing financial transparency, and strengthening the overall health of our company. What sets Filip apart is not just his expertise but his hands-on approach. He doesn’t just identify areas for improvement—he rolls up his sleeves and gets the work done, a great example of InSphero attitude! His keen insights, excellent experience in diverse management roles, and dedication have led to concrete improvements that we internally, but also our customers experience everyday: faster turn-around times, more concise product portfolio, as well as quick and precise communication. Beyond his professional capabilities, Filip is a dependable, constructive and collegial presence on our C-level team mixing Scandinavian and Swiss qualities. His professionalism, coupled with his collaborative spirit, optimism and humor, makes him a perfect fit for InSphero's leadership culture. Given his outstanding contributions and his ability to deliver results, I am happy to share that Filip will now take on the role of Chief Operating Officer alongside his CFO responsibilities. I have no doubt that Filip will continue to drive positive change and lead us to even greater heights. Congratulations, Filip! Madhu Lal Nag, MBS PhD, Paul Edgard Clémençon #Leadership #Teamwork #InSphero #CFO #COO #Gratitude #Growth
-
👏 Monday Unveils Breakthrough: We’re thrilled to announce our 🤝collaboration with Breakthrough T1D and the Université libre de Bruxelles (ULB) Center for Diabetes Research! Supported by Breakthrough T1D’s IDDP program, this partnership focuses on uncovering novel treatment strategies for #type1diabetes, aiming to protect and preserve vital insulin-producing beta cells in the pancreas. Together with Dr. Decio L. Eizirik and his team at ULB, we will explore innovative approaches poised to revolutionize #T1D treatment. Dr. Burcak Yesildag, VP of Islet Biology: “Unlike traditional approaches that focus solely on the immune system, our strategy addresses the misguided dialogue between the immune system and #betacells in T1D. With Breakthrough T1D support, we are excited to leverage our physiologically relevant 3D cell models to explore new therapeutic avenues that could revolutionize T1D treatment.” Stay tuned for updates as we embark on this groundbreaking journey! Read the full press release through the link in comments 👇 Burcak Yesildag Alexandra Title Sayro Jawurek Chantal Rufer Ben Kodiyan Lynn Scherpe Madhu Lal Nag, MBS PhD Jan Lichtenberg Filip Henzler Paul Edgard Clémençon Wolfgang Moritz Arumugham (Ragoo) Raghunathan Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Rositsa Hadzhipetrova Tina Žel #Type1Diabetes #3DCellCulture #OrganOnChip #InSphero
-
🫵 Are you an oncology researcher frustrated by the limitations of 2D models and the tedious nature of animal models? 👩🔬🧑🔬👨🔬 Being a team of experienced researchers, we understand your 🤦♀️ pain and the challenge of bridging the gap between a brilliant idea 💡and the actual execution of your experiment. That is why we developed an easy and convenient 3D cell culture solution for you called Always Ready Cryo Tissues – or short ❄️ARCTis™❄️! Whether you’re testing #smallmolecules or exploring new biologics, ARCTis™ human tumor models empower you to dive straight into your experiments with minimal preparation. It’s as easy as 1, 2…#3D! Discover our extensive portfolio of 3D tumor models and transform the way you conduct research. 👉Follow the link in the comments to learn more. 🤫PS. This post might be inspired by the 🔥 heat outside, but our solutions are all about keeping your research ❄️cool❄️ and efficient! Nils Goedecke Simon Stroebel, PhD Simon Hutter Tala Issa Laure-Anne Ligeon Irina Agarkova Maja Nedic Matthias Zbinden Charlotte Veser Olivier Frey Jan Lichtenberg Wolfgang Moritz Madhu Lal Nag, MBS PhD Paul Edgard Clémençon Arumugham (Ragoo) Raghunathan Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Tina Žel Rositsa Hadzhipetrova ATCC Brian Shapiro, Ph.D. Viqar Aslam Utsav Sharma, Ph.D. #3dinvitro #cancerresearch #tumormodels #drugdiscovery #cryopreservation #oncologyresearch
-
🌟 Advancing Drug Discovery in Liver Disease: The MASH CALL Initiative 🌟 🔍 Identifying the best candidates early on to minimize attrition rates is one of the biggest challenges in #drugdiscovery. To address this, there's an increasing need for advanced in vitro 3D models that can reliably predict clinical outcomes. These models need to be #scalable and #costeffective, compatible with #automation, and capable of delivering diverse readouts for complex phenotypic analysis. Our 3D InSight™ MASH model consists of primary human ✔️hepatocytes, ✔️Kupffer cells, ✔️endothelial cells, and ✔️stellate cells. These healthy liver spheroids are exposed to steatotic and pro-inflammatory media conditions, which over 🗓10 days result in the main hallmarks of human MASH (steatosis, inflammation, and fibrosis). At InSphero we take the next step in drug discovery for MASH by launching the MASH CALL Initiative – an exciting opportunity to push the boundaries of what's possible in drug discovery and bring new, effective treatments to the market faster 🚀 Join the MASH CALL by 🗓 September 6 and let's work together to revolutionize the future of MASH therapeutics! 💊 Learn more via the link in comments 👇 Francisco Verdeguer Radina Kostadinova, PhD Jesus Francisco Glaus Garzon Angelina Freitag Joel Zvick Philip Vonschallen Paul Edgard Clémençon Arumugham (Ragoo) Raghunathan Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Madhu Lal Nag, MBS PhD Jan Lichtenberg Rositsa Hadzhipetrova Tina Žel #DrugDiscovery #Innovation #Healthcare #MASHCALL #Pharma #3DModels #PhenotypicAnalysis